346 related articles for article (PubMed ID: 22379067)
1. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Heo JY; Choi WS; Lee J; Kim WJ
Clin Vaccine Immunol; 2012 May; 19(5):638-41. PubMed ID: 22379067
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
[TBL] [Abstract][Full Text] [Related]
3. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
6. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
Clark TW; Pareek M; Hoschler K; Dillon H; Nicholson KG; Groth N; Stephenson I
N Engl J Med; 2009 Dec; 361(25):2424-35. PubMed ID: 19745215
[TBL] [Abstract][Full Text] [Related]
7. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
[TBL] [Abstract][Full Text] [Related]
8. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
9. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ
Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427
[TBL] [Abstract][Full Text] [Related]
10. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
[TBL] [Abstract][Full Text] [Related]
14. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.
Viganò A; Giacomet V; Pariani E; Giani E; Manfredini V; Bedogni G; Erba P; Amendola A; Zanetti A; Zuccotti G
Clin Vaccine Immunol; 2011 Sep; 18(9):1503-9. PubMed ID: 21795458
[TBL] [Abstract][Full Text] [Related]
16. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
17. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
[TBL] [Abstract][Full Text] [Related]
18. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.
Son J; Lee SB; Lee DW; Kim IY; Lee SJ; Lee SM; Song SH; Seong EY; Kwak IS
Clin Exp Nephrol; 2013 Apr; 17(2):275-83. PubMed ID: 22990301
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
Noh JY; Song JY; Choi WS; Lee J; Seo YB; Kwon YJ; Ko GJ; Cha DR; Kang YS; Lee YK; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
